For instance, CD44+ hepatocellular carcinoma xenografts treated with CD44-CAR T cells demonstrated a significant decrease in tumor volume in comparison with mock T and normal T cells; CD44 tumor volumes were unchanged in comparison with CD44-CAR T, mock T and normal T cells (Wang et al., 2020). This evidence concerns the gene CD44 and hepatocellular carcinoma.